Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

Completed · Phase 3

Conditions studied: Kidney Transplant Rejection

In brief

The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

Key facts

Study ID
NCT03363945
Run by
Medeor Therapeutics, Inc.
People needed
30
Starts
2018-03-15
Expected to finish
2024-04-11
Last updated by the study team
2024-06-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.